Overview

TXA127 for the Treatment of Severe COVID-19

Status:
Completed

Trial end date:
2021-06-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127) prevents acute kidney injury and deterioration into multi-organ failure in patients with severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study drug. The drug will be administered intravenously for 3 hours once each day for 10 days consecutively.

Phase:

Phase 2

Details

Lead Sponsor:

Columbia University

Collaborator:

Constant Therapeutics LLC

Treatments:

Angiotensin I (1-7)